Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

NCT07304739 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Furmonertinib
DRUG: Intrathecal chemotherapy
RADIATION: Stereotactic radiotherapy

Sponsor

Tianjin Medical University Cancer Institute and Hospital